OSO. V. Syma

O. V. Syma

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


O. V. Syma has a total of 5 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Contraindications to Surgical Treatment of Tumor Thrombosis of the Inferior Vena Cava in Renal Cell Carcinoma

    by V. I. Rusin, S. O. Boiko, V. V. Rusin, S. Sh. S. Boiko, O. V. Syma

    Objective. Based on clinical experience, to review and supplement the contraindications for surgical treatment of tumor thrombosis of the inferior vena cava in renal cell carcinoma. Materials and Methods. The results of clinical, laboratory, ultrasound (with Doppler), radiological, and morphological examination and treatment of 162 patients with renal cell carcinoma complicated by tumor thrombosis of the inferior vena cava (stages 0–IV) were analyzed. The general condition of patients was assessed using the ECOG scale and according to the ASA physical status classification. Radical surgical treatment was performed in 159 (98.1%) patients. All surgical procedures were performed via laparotomy. In 3 (1.9%) patients, contraindications to surgery were identified, so targeted therapy was selected as the treatment method. Overall survival rates were assessed for patients who underwent nephrectomy and inferior vena cava thrombectomy, and for patients who did not receive surgical treatment. Results. According to the ECOG scale, the general condition was rated as 0 points in 84 (51.9%) patients, 1 point in 61 (37.7%) patients, and 2 points in 17 (10.5%) patients. According to the ASA classification, 130 (80.2%) patients were classified as Class II, and 32 (19.8%) as Class III. No tumor-related venous thrombus was diagnosed in 62 (38.3%) patients, Grade I in 34 (21.0%), Grade II in 31 (19.1%) patients, Grade III in 23 (14.2%) patients, and Grade IV in 12 (7.4%). Tumor thrombus invasion of varying degrees into the wall of the inferior vena cava was histologically confirmed in 68 (70.1%) of 97 patients with tumor thrombus grades I–IV who underwent surgical treatment. There were no intraoperative deaths. Mortality in the early postoperative period was 0.6% (1 patient out of 159 died). Three patients who did not undergo surgical treatment had grade IV tumor venous thrombus with extensive invasion of the inferior vena cava wall, extending to its supradiaphragmatic segment. The median overall survival for patients who underwent surgical treatment was 48 months, and for patients who received only targeted therapy, it was 11 months. Conclusions. Absolute contraindications to surgical treatment of renal cell carcinoma complicated by tumor thrombosis of the inferior vena cava are proposed, to supplement the technical contraindication–extensive tumor invasion of the inferior vena cava extending in the cranial direction, involving the main hepatic veins, the supradiaphragmatic segment of the inferior vena cava, and the right atrium. In cases of local invasion of a tumor thrombus into the intima of any segment of the inferior vena cava or into the endocardium, surgical treatment is not contraindicated.

  • Open Access

    Surgical treatment of the inferior vena cava (IVC) leiomyosarcoma

    by V. V. Rusin, F. V. Gorlenko, S. Sh. S. Boiko, O. V. Syma

    Objective. To propose and introduce a diagnostic-treatment algorithm for the inferior vena cava (IVC) leiomyosarcoma into clinical practice. Materials and methods. During last 30 years in Zakarpattya Regional Clinical Hospital Named After Andriy Novak and Zakarpattya Antitumoral Centre were operated 8 patients, suffering the IVC leiomyosarcoma - 7 (87.5%) women and 1 (12.5%) man. Median of the patients' age have constituted 57 yrs old. For characterization of the affection localization in accordance to own views on the subject the classification of the IVC division into 7 segments was applied: infrarenal, іnterrenal, suprarenal, retrohepatic, іnfradiaphragmatic, supradiaphragmatic,іntracardial. Іntravasal localization of the tumor was observed in 3 (37.5%), extravasal - in 1 (12.5%), mixed - in 4 (50%) patients. In all the patients the open laparotomy approach was applied: in 1 (12.5%) patient median laparotomy was performed, and in 7 (87.5%) - bilateral subcostal laparotomy of a «Chevron» type. For the IVC alloprosthesis in 6 (75%) patients a politetrafluoroethylene prosthesis was applied, while in 2 (25%) - Gore-tex prosthesis of 18-22 mm in diameter. In 5 (62.5%) patients circular resection with the IVC alloprosthesis was done, in 2 (25%) - circular resection, the IVC alloprosthesis and іmplantation of right and left renal veins into the prosthesis, and in 1 (12.5%) - circular resection, alloprosthesis of IVC and implantation of left renal vein into prosthesis. Results. The operation median duration have constituted 215 (160 - 320) min, while the average volume of the blood loss - 305 (250 - 500) ml. The Degree II postoperative complications in accordance to classification of Clavien-Dindo were registered in 2 (25%) patients. Pulmonary thromboembolism, venous thrombosis, thrombosis of prosthesis, as well as intraoperative or immediate postoperative lethality were not observed. In 7 (87.5%) patients a radical intervention was performed. In 3 (37.5%) patients a remote hepatic and pulmonary metastases have been developed, leading to their death in terms from 10 to 34 mo. General one-, two- and a three-ear survival have constituted 87.5, 75 and 62.5%, accordingly. Conclusion. Surgical approach of a «Chevron» type and the staged dissection of IVC guarantees an adequate visualization of its іnfra-, іnter- and suprarenal segments. The «piggyback» procedure of hepatic mobilization and Pringle maneuver constitute necessary parts on the stage of dissection in retrohepatic, infradiaphragmatic and supradiaphragmatic segments of IVC. Radical tumoral excision with the IVC prosthesis and implantation, when needed, of renal or hepatic veins - is the only one possibility for improvement of the patients' quality of life in the IVC leiomyosarcoma.